Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells

Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells

Lobaplatin is a third-generation platinum-based antineoplastic agent and is widely used for osteosarcoma treatment before and after tumor removal. However, treatment failure often results from lobaplatin drug resistance. In our study, we found that SaOS-2 and SOSP-9607 osteosarcoma cells became less...

Full description

Bibliographic Details
Main Authors: Huan Wang, Bin Li, Kang Yan, Yonghong Wu, Yanhua Wen, Yunyan Liu, Pei Fan, Qiong Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
osteosarcoma
rhIL-6 intervention
lobaplatin
liquid chromatography-tandem mass spectrometry
protein–protein interaction
FUBP1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.602712/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.602712/full

Similar Items